logo
NVDA Stock Overvalued At $140?

NVDA Stock Overvalued At $140?

Forbes6 days ago

CHONGQING, CHINA - MAY 25: In this photo illustration, the logo of NVIDIA Corporation is displayed ... More on a smartphone screen, with the latest stock market chart of the company in the background, reflecting investor sentiment and recent trading activity, on May 25, 2025, in Chongqing, China. NVIDIA is a leading American technology company renowned for its graphics processing units (GPUs), artificial intelligence (AI) computing platforms, and data center solutions. (Photo Illustration by)
Yes, we think so. Currently, Nvidia (NASDAQ; NVDA) stock trades at 44 times its trailing earnings of $3.19 per share. This figure aligns with the stock's average P/E ratio over the last two years, and growth has remained solid thus far. The real question is whether this growth will continue, which we'll delve into in the sections below. First, let's examine what happened in the recently reported Q1.
Nvidia recently announced its fiscal first-quarter results for the period ending April 2025, reporting adjusted earnings of $0.96 per share on revenues of $44.1 billion. This represents a significant 69% year-over-year increase in sales and a 57% growth in earnings. The company performed better than Wall Street's expectations, which had projected adjusted earnings of $0.93 per share on sales of $44.3 billion. However, the company's outlook of $45 billion in Q2 sales missed the Street's estimates of around $46 billion. This weaker guidance was primarily due to an expected $8 billion hit to the top line from recent export restrictions on the company's H20 chips bound for China. During the quarter, the company spent $14.1 billion on share repurchases and paid $244 million in dividends. Separately, see – Buy, Sell, or Hold AVGO Stock?
After exceeding analyst estimates, Nvidia's stock surged around 5% in after-hours trading on Wednesday, May 28. That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative - having outperformed the S&P 500 and generated returns exceeding 91% since its inception.
Looking at segments, data center revenue reached $39.1 billion, marking a 73% year-over-year increase. Gaming & AI PC was up 42%, Professional Visualization sales grew 19%, and Automotive & Robotics revenue increased by 72%. This growth was primarily driven by continued strong demand for the company's GPU chips, which are heavily used in generative AI applications.
Nvidia has also ramped up large-scale production of its latest Blackwell AI supercomputers. These new chips, with their advanced AI capabilities and premium pricing, have contributed significantly to top-line growth. Nvidia's Blackwell cloud is now available on major platforms including AWS, Google Cloud, Microsoft Azure, and Oracle Cloud Infrastructure. Microsoft has been a substantial buyer of these Blackwell chips. However, the company's gross margins of 61% were down 1,790 basis points from 78.9% in the year-ago quarter. Excluding the one-time charge from H20 sales restrictions, the gross margin would have been 71.3%.
Nvidia stock is a market darling, and its Q1 performance may lead to a further spike, possibly pushing it towards its 52-week high. However, consider this: can such growth truly be sustained? Is a valuation of 44 times trailing earnings justified?
Nvidia's phenomenal growth is a recent phenomenon, and it might not last. Indeed, the entire AI boom could fizzle, or perhaps large AI models, in particular, could be deemed unnecessary. Deepseek's demonstration that smaller models can perform just as well, without even utilizing Nvidia's latest chips, raises questions.
However, what are the odds that Nvidia's chips will cease to be in high demand? That's where the speculation begins.
Nvidia's revenues have grown by more than 80% annually for each of the last three years, with last year exceeding 100% growth. Could this growth decelerate to 60% or even 40%?
It almost certainly has to—and soon!
Why?
Nvidia's largest customers include tech giants like Microsoft, Google, Meta, and Amazon. Each of these companies spent tens of billions last year on Nvidia chips. Can these companies continue to increase their spending on Nvidia chips by 100% year after year, especially when their own revenues are growing at only about 15% annually?
No, absolutely not.
The era of Nvidia's 80-100% growth must eventually come to an end. When this period of rapid expansion concludes, Nvidia's valuation will likely drop significantly. In fact, we currently estimate Nvidia's Valuation to be around $100 per share, reflecting a downside of over 25% from the current levels. Note that we will revise our model shortly to reflect the latest quarterly results.
However, growth could then stabilize at a more sustainable pace of 20-30%, which, while not exceptionally high, is still respectable. That's why you build a portfolio. A resilient one. Balance risk-reward. We did it in spades with the Trefis High Quality (HQ) portfolio. Balancing risk-reward is how HQ outperformed the S&P 500, the Nasdaq, and the Russell 2000. HQ outperformed all of them, and clocked >91% returns since inception!

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Yahoo

time24 minutes ago

  • Yahoo

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@

The Wiretap: Trump Says Goodbye To The AI Safety Institute
The Wiretap: Trump Says Goodbye To The AI Safety Institute

Forbes

time24 minutes ago

  • Forbes

The Wiretap: Trump Says Goodbye To The AI Safety Institute

The Wiretap is your weekly digest of cybersecurity, internet privacy and surveillance news. To get it in your inbox, subscribe here. (Photo by Jim WATSON / AFP) (Photo by JIM WATSON/AFP via Getty Images) The Trump administration has announced plans to reorganize the U.S. AI Safety Institute (AISI) into the new Center for AI Standards and Innovation (CAISI). Set up by the Biden administration in 2023, AISI operated within the National Institute of Standards & Technology (NIST) to research risks in widely-used AI systems like OpenAI's ChatGPT or Anthropic's Claude. The move to dismantle the body had been expected for some time. In February, as JD Vance headed to France for a major AI summit, his delegation did not include anyone from the AI Safety Institute, Reuters reported at the time. The agency's inaugural director Elizabeth Kelly had stepped down earlier in the month. The Commerce Department's announcement marking the change is thin on details about the reorganization, but it appears the aim is to favor innovation over red tape. 'For far too long, censorship and regulations have been used under the guise of national security. Innovators will no longer be limited by these standards. CAISI will evaluate and enhance U.S. innovation of these rapidly developing commercial AI systems while ensuring they remain secure to our national security standards,' said Secretary of Commerce Howard Lutnick. What could be gleaned from Lutnick's paradoxical phrasing – national security-focused standards are limiting, but America needs national security-focused standards – is that it's very difficult to tell just how much the new body will differ from the old one. The announcement goes on to state that CAISI will 'assist industry to develop voluntary standards' in AI, which summed up much of what the old body did. Similarly, just as the AI Safety Institute was tasked with assessing risks in artificial intelligence, CAISI will 'lead unclassified evaluations of AI capabilities that may pose risks to national security.' CAISI will also still be a part of NIST. And, despite Lutnick's apparent disdain for standards, the Commerce press release concludes that CAISI will 'ensure U.S. dominance of international AI standards.' That there's little obvious change between the Institute and CAISI might alleviate any immediate concerns the U.S. is abandoning commitments to keep AI safe. Just earlier this year, a coalition of companies, nonprofits and academics called on Congress to codify the Institute's existence before the year was up. That included major players like OpenAI and Anthropic, both of which had agreements to work with the agency on research projects. What happens to those is now up in the air. The Commerce Department hadn't responded to a series of questions at the time of publication, and NIST declined to comment. Got a tip on surveillance or cybercrime? Get me on Signal at +1 929-512-7964. (Photo by Melina Mara-Pool/Getty Images) Unknown individuals have impersonated President Trump's chief of staff Susie Wiles in calls and texts to Republican lawmakers and business executives. Investigators suspect the perpetrators used artificial intelligence to clone Wiles' voice. One lawmaker was asked by the impersonator to assemble a list of individuals for potential presidential pardons, according to the Wall Street Journal. It's unclear that motives lay behind the impersonation, or how they pulled the stunt off. Wiles had told confidantes that some of her contacts from her personal phone had been stolen by a hacker. A Texas police officer searched Flock Safety's AI-powered surveillance camera network to track down a woman who had carried out a self-administered abortion, 404 Media reports. Because the search was conducted across different states, experts raised concerns about police using Flock to track down individuals getting abortions in states where it's legal before going back home to a state where it's illegal. The cops said they were simply worried about the woman's safety. Nathan Vilas Laatsch, a 28-year-old IT specialist at the Defense Intelligence Agency, has been arrested and charged with leaking state secrets after becoming upset at the Trump administration. The DOJ did not specify to which country Laatsch allegedly tried to pass secrets, sources told the Washington Post it was Germany. He was caught out by undercover agents posing as interested parties, according to the DOJ. Europol announced it had identified more than 2,000 links 'pointing to jihadist and right-wing violent extremist and terrorist propaganda targeting minors.' The agency warned that it had seen terrorists using AI to generate content like short videos and memes 'designed to resonate with younger audiences.' A 63-year-old British man, John Miller, was charged alongside a Chinese national by the Department of Justice with conspiring to ship missiles, air defense radar, drones and unspecified 'cryptographic devices' to China. They're also charged with trying to stalk and harass an individual who was planning protests against Chinese president Xi.

Will new nuclear energy deals generate FOMO mentality in Big Tech?
Will new nuclear energy deals generate FOMO mentality in Big Tech?

Yahoo

time29 minutes ago

  • Yahoo

Will new nuclear energy deals generate FOMO mentality in Big Tech?

Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean nuclear energy plant starting in 2027. Mizuho Americas managing director and senior analyst of utilities Anthony Crowdell discusses the Constellation-Meta deal, as well as other energy agreements as grid demand soars to power AI data centers, and the regulation around nuclear plants after President Trump signed an executive order in May to ease restrictions around nuclear reactor development. Catch Yahoo Finance's interview with Nano Nuclear Energy founder, executive chairman, and president Jay Yu on the nuclear energy landscape. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store